Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers
Esther H. Lips(Leiden University Medical Center), Petra M. Nederlof(The Netherlands Cancer Institute), Anne M.M. Oonk(Deventer Ziekenhuis), Lennart Mulder(The Netherlands Cancer Institute), Frans B.L. Hogervorst(The Netherlands Cancer Institute), Lizet E. van der Kolk(The Netherlands Cancer Institute), Jelle Wesseling(Leiden University Medical Center), Sjoerd Rodenhuis(The Netherlands Cancer Institute), Alex L.T. Imholz(Deventer Ziekenhuis)
Cited by 241
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
K-<i>ras</i>Oncogene Activation as a Prognostic Marker in Adenocarcinoma of the Lung
|New England Journal of Medicine|1990|811
Impairment of Cognitive Function in Women Receiving Adjuvant Treatment for High-Risk Breast Cancer: High-Dose Versus Standard-Dose Chemotherapy
|JNCI Journal of the National Cancer Institute|1998|768
Mutational Activation of the K-<i>ras</i>Oncogene
|New England Journal of Medicine|1987|540